Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
clinical trial
Press Enter · cited answer in seconds
0 sources
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
Summary
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics is a clinical trial[1].
Key Facts
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics is in the country of United States[2].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's instance of is recorded as clinical trial[3].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's start time is recorded as +2022-09-01T00:00:00Z[4].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's end time is recorded as +2024-12-31T00:00:00Z[5].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's main subject is recorded as psoriasis[6].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's number of participants is recorded as {'unit': '1', 'amount': '+56'}[7].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's title is recorded as Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics in Ustekinumab Responders Versus Non-responders[8].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[9].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's ClinicalTrials.gov ID is recorded as NCT05270733[10].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+89'}[11].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's research intervention is recorded as ustekinumab[12].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's research intervention is recorded as dermatologic drug[13].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's clinical trial phase is recorded as phase IV clinical trial[14].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's research site is recorded as Case Western Reserve University[15].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's research subject recruitment status is recorded as not yet recruiting[16].
- Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics's study type is recorded as interventional study[17].